Share this story:

Elixxer's Investment in Australian Company Makes 120% Gain through Recent Acquisition



Elixxer Ltd.
 

Little Green Pharma Acquires Danish Cannabis Facility

 

MONTRÉAL – TheNewswire - June 24, 2021 -- Elixxer Ltd. (TSXV:ELXR) (OTC:ELIXF) (FRA:2LQA) (“ Elixxer ” or the “ Company ”) is pleased to announce that its largest holding (27.4M shares) of Little Green Pharma Ltd. (“LGP”), has acquired a cannabis GACP cultivation and EU-recognised GMP-licensed cannabis production facility located in Denmark (the “Denmark Facility”), as well as the receipt of firm commitments to raise A$27.2 million by way of placement to institutional and sophisticated investors.

Ferras Zalt, Chairman and Interim CEO of Elixxer commented, “Our decision to invest in LGP was calculated, and our continued strategy of seeking and investing in companies that are leading this industry, is having significant returns. LGP’s acquisition is an efficient use of its capital.”

Currently, LGP has a market cap of $141M on the ASX, and Elixxer holds 27.4M or 13.4%. On June 24, 2021, the closing price of LGP was $0.81 per share on the ASX.  LGP Share Price  Elixxer’s initial investment in LGP was $8.2M.  For details on Elixxer’s initial investment in LGP, please see the Company’s press releases of October 12, 2017, December 14, 2017, February 16, 2018, May 22, 2019 and August 26, 2019.


Click Image To View Full Size


For a full update from LGP’s AGM update please click:
https://investor.littlegreenpharma.com/site/showdownloaddoc.aspx?AnnounceGuid=8375cb79-32bb-4e35-957d-e19fb3f59f69&TE=lenigas@monaco-capital.com

 

-30-

About Elixxer Ltd. (www.Elixxer.com)

Elixxer is a Canadian public company listed on the TSX Venture Exchange (TSX-V: ELXR) and the US OTC-QB exchange (OTCQB: ELIXF).

Through its partners, Elixxer presently has significant interests in Australia, Jamaica, Switzerland, Italy and Canada. The Company’s strategy is to seek and invest in emerging leaders.

For further information, please contact: 

Ferras Zalt, Chairman and Interim CEO: +44 20 7409 6680; ferras@elixxer.com 

Caution Regarding Press Releases

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice Regarding Forward Looking Statements

This press release may contain forward-looking statements with respect to Elixxer and its operations, strategy, investments, financial performance and condition. These statements can generally be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of Elixxer could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under “Risk Factors and Risk Management” in Elixxer’s most recent Management’s Discussion and Analysis filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to Elixxer and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release, and Elixxer has no obligation to update such statements, except to the extent required by applicable securities laws.